MGNX (Macrogenics) OCF Margin %: -172.38% (As of Mar. 2026)

What is Macrogenics OCF Margin %?

Macrogenics MGNX +1.92% 47 OCF Margin % is -172.38% as of Mar. 2026. GuruFocus rates MGNX with a GF Score™ of 47/100 and a GF Value™ of $4.09 (Modestly Overvalued). The stock has 8 warning signs investors should review. Among 959 Biotechnology companies, Macrogenics ranks better than 53.18% on this metric.

OCF Margin % is calculated as Cash Flow from Operations divided by its Revenue. Macrogenics's Cash Flow from Operations for the three months ended in Mar. 2026 was $-35.8 Mil. Macrogenics's Revenue for the three months ended in Mar. 2026 was $20.8 Mil. Therefore, Macrogenics's OCF Margin % for the quarter that ended in Mar. 2026 was -172.38%.

As of today, Macrogenics's current OCF Yield % is -23.03%.

The historical rank and industry rank for Macrogenics's OCF Margin % or its related term are showing as below:

MGNX' s OCF Margin % Range Over the Past 10 Years
Min: -261.3 Med: -86.22 Max: 9.26
Current: -44.54

During the past 13 years, the highest OCF Margin % of Macrogenics was 9.26%. The lowest was -261.30%. And the median was -86.22%.

MGNX's OCF Margin % is ranked better than
53.18% of 959 companies
in the Biotechnology industry
Industry Median: -66.52 vs MGNX: -44.54

Macrogenics OCF Margin % Related Terms

Macrogenics OCF Margin % Historical Data

* Premium members only.

The historical data trend for Macrogenics's OCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Macrogenics OCF Margin % Chart

Macrogenics Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

OCF Margin %

Get a 7-Day Free Trial

-190.14

-57.97

-133.12

-45.59

-54.21

Macrogenics Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
OCF Margin %	Get a 7-Day Free Trial															-355.44	-211.25	-41.44	104.35	-172.38

MGNX vs CNTX, TARA, ACIU: OCF Margin % Comparison

For the Biotechnology subindustry, Macrogenics's OCF Margin %, along with its competitors' market caps and OCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Macrogenics OCF Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Macrogenics's OCF Margin % distribution charts can be found below:

* The bar in red indicates where Macrogenics's OCF Margin % falls into.

Save Embed

47GF Score

Macrogenics Inc MGNX

OCF Margin % is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Macrogenics OCF Margin % Calculation

OCF Margin % is the ratio of Cash Flow from Operations divided by net sales or Revenue, usually presented in percent.

Macrogenics's OCF Margin for the fiscal year that ended in Dec. 2025 is calculated as

OCF Margin	=	Cash Flow from Operations (A: Dec. 2025 )	/	Revenue (A: Dec. 2025 )
	=	-81.04	/	149.5
	=	-54.21 %

Macrogenics's OCF Margin for the quarter that ended in Mar. 2026 is calculated as

OCF Margin	=	Cash Flow from Operations (Q: Mar. 2026 )	/	Revenue (Q: Mar. 2026 )
	=	-35.811	/	20.775
	=	-172.38 %

Frequently Asked Questions Learn more about OCF Margin % →

What does a OCF Margin % of -172.38% mean?

Macrogenics (MGNX) has a OCF Margin % of -172.38% as of Mar. 2026. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Macrogenics and its competitors. According to the industry distribution chart, Macrogenics ranks #449 out of 959 companies in the Biotechnology industry, placing it in the top 46.8%.

Is Macrogenics' OCF Margin % too high?

Macrogenics' current OCF Margin % is -172.38%. Based on the distribution chart, Macrogenics ranks #449 out of 959 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Macrogenics has a GF Score™ of 47/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.

How does Macrogenics' OCF Margin % compare to CNTX and TARA?

According to the Biotechnology industry distribution chart, Macrogenics ranks #449 out of 959 companies for OCF Margin %. This puts Macrogenics in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good OCF Margin % for a Biotechnology company?

A good OCF Margin % depends on the Biotechnology industry context. However, OCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high OCF Margin % mean?

A high OCF Margin % can signal that a stock is expensive relative to its fundamentals. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Macrogenics and its competitors. Macrogenics's current OCF Margin % is -172.38%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Macrogenics stock overvalued right now?

Based on GuruFocus' analysis, Macrogenics (MGNX) is currently considered Modestly Overvalued. The stock's GF Value™ is $4.09, compared to a current price of $4.76 — trading 16.4% above its estimated fair value. The current OCF Margin % is -172.38%. Macrogenics' overall GF Score™ is 47/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is OCF Margin % calculated?

OCF Margin % is calculated from a company's financial statements. For Macrogenics (MGNX), the current OCF Margin % is -172.38% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Macrogenics (MGNX) Overvalued in 2026?

Based on GuruFocus' analysis, Macrogenics stock appears to be overvalued. The current stock price of $4.76 is trading 16.4% above its estimated GF Value™ of $4.09. GuruFocus considers Macrogenics to be Modestly Overvalued.

Key valuation signals for MGNX:

OCF Margin %: -172.38%
GF Value™: $4.09 vs. price of $4.76 (16.4% above fair value)
GF Score™: 47/100 with 8 warning signs

No single metric tells the full story. See the MGNX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Macrogenics Business Description

Industry Healthcare Biotechnology

Comparable Companies CNTX TARA ACIU NVCT ALXO TRDA SABS CDXS FHTX AVXL VRTX REGN XBRU:UCB XBRU:ARGX XKRX:207940 ALNY RVMD ASX:CSL ONC XKRX:068270

Other Exchanges M55:Germany

Address 9704 Medical Center Drive, Rockville, MD, USA, 20850

Website https://www.macrogenics.com

Macrogenics Inc is a clinical-stage biopharmaceutical company focused on developing antibody-based therapeutics for the treatment of cancer. The company is currently developing therapeutics utilizing multiple modalities, including antibody-drug conjugates (ADCs) and multi-specific antibodies (which it refers to as DART and TRIDENT molecules). It is advancing three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload. Its segment is developing and commercializing monoclonal antibody-based therapeutics.

47GF Score

Get the complete analysis for MGNX

OCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$4.76

Price

$4.09

GF Value

View MGNX Analysis

See OCF Margin % data for all stocks →